Related Experiment Video

Updated: Jul 21, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

223

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors

Weronika Frąk1, Joanna Hajdys1, Ewa Radzioch1

  • 1Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Żeromskiego 113, 90-549 Łódź, Poland.

Biomedicines
|July 29, 2023
PubMed

Insights

Sodium/glucose cotransporter 2 (SGLT2) inhibitors show significant cardiovascular and renal benefits beyond diabetes management. These SGLT2 inhibitors offer promising therapeutic potential for cardiovascular diseases, warranting further investigation.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVD) represent a leading global cause of mortality.
  • Sodium/glucose cotransporter 2 (SGLT2) inhibitors were initially developed for type 2 diabetes.
  • These drugs exhibit benefits extending beyond glycemic control.

Purpose of the Study:

  • To review the role of SGLT2 inhibitors in managing cardiovascular diseases.
  • To discuss specific SGLT2 inhibitors including empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and bexagliflozin.
  • To highlight their potential as therapeutic targets for CVD.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of the cardiovascular and renal protective effects of SGLT2 inhibitors.
  • Discussion of mechanisms of action and clinical applications.

Main Results:

  • SGLT2 inhibitors demonstrate significant cardiovascular benefits.
  • Renal protection is a key finding across multiple SGLT2 inhibitors.
  • Benefits are observed in patients with and without type 2 diabetes.

Conclusions:

  • SGLT2 inhibitors are a promising therapeutic class for cardiovascular diseases.
  • These agents offer multifaceted benefits including renal protection.
  • Further research is needed to fully elucidate mechanisms and optimize treatment strategies.

Keywords:
bexagliflozindiabetes mellitusheart failuresodium/glucose cotransporter 2 (SGLT2) inhibitors

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

286
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

658

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
208
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K